Results 71 to 80 of about 22,968 (195)

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib [PDF]

, 2018
Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor-positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition.
Björklund, Mikael, Gierliński, Marek, Gothenburg University., Göteborgs universitet., Härtlova, Anetta,, Jansen, Valerie M, Miettinen, Teemu P, Peltier, Julien, Trost, Matthias   +8 more
core   +3 more sources

Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study

Frontiers in Pharmacology
IntroductionIpatasertib is a potent, highly selective, small molecule AKT inhibitor that has been evaluated in combination with palbociclib and fulvestrant for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor two ...
Kit Wun Kathy Cheung, Ksenia Arzumanova, Victor Poon, Adam Harris, Ryan Johnson, Frauke Schimmoller, Rucha Sane   +6 more
doaj   +1 more source

An Update on Early‐Onset Breast Cancer: Incidence, Risk Factors, Genetic Testing, and Treatment

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Early‐onset breast cancer presents in patients typically under the age of 40, while very early‐onset breast cancer is usually viewed as breast cancer occurring before the age of 35. Early‐onset breast cancer demonstrates specific molecular properties and has worse outcomes compared to its late‐onset breast cancer counterpart.
Leila Jahangiri
wiley   +1 more source

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials

Cancer Medicine, 2019
Background Palbociclib is a small‐molecule, cyclin‐dependent kinase 4 and 6 inhibitor, which prevents phosphorylation of the retinoblastoma (Rb) protein and inhibits cell‐cycle progression from G1 to S phase.
Linghong Guo, Yuanyuan Hu, Xi Chen, Qingfang Li, Benling Wei, Xuelei Ma   +5 more
doaj   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, Volume 159, Issue 1, Page 210-223, 1 July 2026.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. [PDF]

, 2019
BackgroundPALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Diéras, Véronique, Ettl, Johannes, Finn, Richard S, Gauthier, Eric, Gelmon, Karen, Harbeck, Nadia, Joy, Anil Abraham, Lu, Dongrui R, Mori, Ave, Rugo, Hope S, Schnell, Patrick, Verma, Sunil   +11 more
core  

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, Volume 159, Issue 1, Page 244-256, 1 July 2026.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer

Nature Communications
Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal role in cell cycle and cancer development. Targeting CDK4/6 has demonstrated promising effects against breast cancer.
Yi Zhang, Shuyan Zhou, Yan Kai, Ya-qin Zhang, Changmin Peng, Zhuqing Li, Muhammad Jameel mughal, Belmar Julie, Xiaoyan Zheng, Junfeng Ma, Cynthia X. Ma, Min Shen, Matthew D. Hall, Shunqiang Li, Wenge Zhu   +14 more
doaj   +1 more source

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

Cancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou   +12 more
wiley   +1 more source

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

BMC Cancer
Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i).
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group   +11 more
doaj   +1 more source